CD4

Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors

Retrieved on: 
Monday, September 12, 2022
Bag valve mask, GCT, SD, PK, Safety, Nivolumab, CD8, Patient, U.S. Securities and Exchange Commission, Oncology, NASDAQ, CD4, Neoplasm, CCR, Drug, Circulating tumor DNA, ESMO, OI, PVR, TIGIT, Annual general meeting, Biomarker, Company, BOS, Annual report, Uvea, DCR, DNA, Osteogenesis imperfecta, Monaco Age Oncologie, Cervical cancer, RECIST, Phase, Ovarian cancer, European Society for Medical Oncology, Senior, Degenerative disease, Partnership, Forward-looking statement, NK, Security (finance), GLOBE, Therapy, CPS, AATD, Form 6-K, IL2, ORR, MMR, Uveal melanoma, Respiratory tract, PD-L1, PD-1, Pharmaceutical industry, CD226, EU, Ultragenyx

LONDON and MOUNTAIN VIEW, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical stage biopharmaceutical company focused on rare diseases and oncology, today reported updated clinical data and promising biomarker data from ACTIVATE, a Phase 1b/ 2 study of anti-TIGIT antibody, etigilimab, in combination with nivolumab, in select recurrent advanced / metastatic solid tumors. These biomarker data were presented at a poster session at the 2022 European Society of Medical Oncology (ESMO) Annual Meeting on September 10, 2022.

Key Points: 
  • These biomarker data were presented at a poster session at the 2022 European Society of Medical Oncology (ESMO) Annual Meeting on September 10, 2022.
  • Of interest, biomarker analysis showed that the 2 cervical subjects with complete responses exhibited higher levels of PVR, TIGIT as well as high CD226+CD8+ co-expression.
  • No evaluable tissue for biomarker analysis was available for the third patent with a complete response.
  • Biomarker data presented at ESMO 2022 evaluated tumors for baseline expression of PVR, TIGIT, PD-L1 and CD226 by multiple modalities including validated IHC assays.

Apexigen Presents New Data from a Phase 2 Trial Evaluating its CD40 Antibody, Sotigalimab, in Combination with Neoadjuvant Chemoradiation in Patients with Resectable Esophageal and Gastroesophageal Junction Cancers at ESMO Congress 2022

Retrieved on: 
Saturday, September 10, 2022
Time, NASDAQ, Survival, SCC, Securities Act of 1933, Nausea, Histology, Principal, Guillain–Barré syndrome, GEJ, Adenocarcinoma, Securities Exchange Act of 1934, Oncology, Chain reaction, Congress, Cancer, San Francisco, Cytokine release syndrome, AC, SEC, Nasdaq, Monocyte, European Society for Medical Oncology, Vomiting, Adoption, CD8, Therapy, Drug Quality and Security Act, GLOBE, University of California, San Francisco, Radiation, ESMO, Safety, B cell, CD40, CD4, MPR, Patient, Tumor microenvironment, Medicine, Neoplasm, Perception, SAN, Squamous cell carcinoma, University, Dysphagia, Pharmaceutical industry, Medical imaging, Residential care, Vaccine

Encouraging pathologic complete response (pCR) rates were observed in patients with both adenocarcinoma (AC) and squamous cell carcinoma (SCC).

Key Points: 
  • Encouraging pathologic complete response (pCR) rates were observed in patients with both adenocarcinoma (AC) and squamous cell carcinoma (SCC).
  • These data were featured in a poster presentation at the European Society for Medical Oncology (ESMO) Congress, being held both virtually and in Paris from September 9-13, 2022.
  • The pathologic complete response rates, an important predictor of survival, compared favorably to historical pCR rates with standard of care treatment alone.
  • Moreover, our study demonstrates that sotiga was able to be safely added to concurrent chemotherapy plus radiation.

IMV Inc. to Present at Two Investor Conferences in September

Retrieved on: 
Thursday, September 1, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Hematological Cancer Research Investment and Education Act, Bladder cancer, DLBCL, CD8, DPX, LinkedIn, TSX, CD4, Survivin, Compliance, Conference, Immune system, Immunotherapy, IMV, Twitter, EDGAR, Terminology, SEDAR, Clinical trial, Mission statement, Forward-looking statement, Management, Vaccine, Nasdaq

H.C. Wainwright 24th Annual Global Investment Conference, New York City

Key Points: 
  • H.C. Wainwright 24th Annual Global Investment Conference, New York City
    Speaker: Andrew Hall, Chief Executive Officer at IMV Inc.
  • Cantor Fitzgeralds Oncology & HemOnc Conference, New York City
    Speaker: Jeremy Graff, Ph.D., Chief Scientific Officer at IMV Inc.
  • IMV Inc. is a clinical-stage immuno-oncology company advancing a portfolio of therapies based on the Companys immune-educating platform, DPX.
  • IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

NIAID/NIH recognizes the potency of UB-421 against multi-drug resistant HIV and receives the FDA approval to conduct a phase 2 clinical trial with UB-421

Retrieved on: 
Wednesday, August 31, 2022
Mortality, HIV disease progression rates, Lists of diseases, CEO, National Institute, Safety, Cancer, HIV-1, Subtypes of HIV, IND, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Infection, Immunoglobulin G, Death, Conditional sentence, Person, Food, NIH, Quality of life, HIV, CD4, ARV, Epitope, Plasma, FDA, NIAID, UBP, ART, Risk, MDR, Viral load, Viremia, Pharmaceutical industry, Vaccine, Neutralizing antibody, Patient

In this trial sponsored by the NIAID/NIH, UBP will be responsible for supplying the investigational drug, UB-421.

Key Points: 
  • In this trial sponsored by the NIAID/NIH, UBP will be responsible for supplying the investigational drug, UB-421.
  • UBP has been collaborating with NIAID since 2015 to study the unique characteristic properties of UB-421 for treatment of HIV.
  • The potent efficacy of UB-421 against HIV clinical isolates resistant to HIV broadly neutralizing antibodies, entry inhibitors, and other antiretroviral drugs is well documented.
  • "We are excited for the NIAID to recognize the effectiveness of UB-421 through extensive collaborative studies, and to sponsor a phase 2 clinical trial in multi-drug resistant HIV patients."

NIAID/NIH recognizes the potency of UB-421 against multi-drug resistant HIV and receives the FDA approval to conduct a phase 2 clinical trial with UB-421

Retrieved on: 
Wednesday, August 31, 2022
Mortality, HIV disease progression rates, Lists of diseases, CEO, National Institute, Safety, Cancer, HIV-1, Subtypes of HIV, IND, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Infection, Immunoglobulin G, Death, Conditional sentence, Person, Food, NIH, Quality of life, HIV, CD4, ARV, Epitope, Plasma, FDA, NIAID, UBP, ART, Risk, MDR, Viral load, Viremia, Pharmaceutical industry, Vaccine, Neutralizing antibody, Patient

In this trial sponsored by the NIAID/NIH, UBP will be responsible for supplying the investigational drug, UB-421.

Key Points: 
  • In this trial sponsored by the NIAID/NIH, UBP will be responsible for supplying the investigational drug, UB-421.
  • UBP has been collaborating with NIAID since 2015 to study the unique characteristic properties of UB-421 for treatment of HIV.
  • The potent efficacy of UB-421 against HIV clinical isolates resistant to HIV broadly neutralizing antibodies, entry inhibitors, and other antiretroviral drugs is well documented.
  • "We are excited for the NIAID to recognize the effectiveness of UB-421 through extensive collaborative studies, and to sponsor a phase 2 clinical trial in multi-drug resistant HIV patients."

Jounce Therapeutics Reports Results from Phase 2 Randomized SELECT Trial Testing 2 Different Doses of Vopratelimab in TISvopra Biomarker-Selected Patients

Retrieved on: 
Tuesday, August 30, 2022
LILRB2, Inflammation, PR, Security (finance), COVID-19, Cis, Induction, PFS, U.S. Securities and Exchange Commission, CCR8, Cancer, Safety, Tumor microenvironment, Research, RNA, Therapy, Macrophage, ILT4, CR, Gilead Sciences, Private Securities Litigation Reform Act, ESMO, SD, CD4, PD-1, Association, ORR, SELECT, Immunotherapy, Immune system, NSCLC, Immunoglobulin G, Marketing, Intellectual property, Public expenditure, PD-L1, Annual report, Congress, ICOS, Patient, Pharmaceutical industry, Fourth, fifth, and sixth derivatives of position

CAMBRIDGE, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today reported top line data from the randomized Phase 2 SELECT trial evaluating vopratelimab (vopra), Jounce’s inducible costimulator (ICOS) agonist, in combination with pimivalimab (pimi) versus pimivalimab alone in immunotherapy naïve, TISvopra biomarker-selected, second line non-small cell lung cancer (NSCLC) patients. The trial tested two pulsatile and differentiated doses of vopra in the combination groups against pimi monotherapy, using as the primary endpoint the mean percent change from baseline in tumor size in all measurable lesions, averaged over 9 and 18 weeks as assessed by central independent radiology review. As the study was powered to detect a 20% absolute difference of the pooled combo doses compared to pimi monotherapy, and the actual difference was 7%, SELECT did not meet its primary endpoint.   In the combination dose cohort with the lowest dose of vopra (0.03mg/kg), interesting trends were observed in both the primary endpoint, with an absolute mean change of 15%, and in the prespecified secondary endpoints of overall response rate (ORR), which was 40% compared to 25% in pimi alone, and landmark six month progression free survival (PFS) of 80% compared to 33% with pimi alone. Consistent with these clinical outcomes, recent mechanistic data in primary human immune cells in vitro supports shorter duration pulsatile dosing of ICOS agonism, with general implications for T cell agonist dosing. Data from SELECT is summarized as follows:

Key Points: 
  • The distribution of PD-L1 scores within the TISvopra positive patients was similar to what would be expected for an unselected patient population.
  • The team did an outstanding job executing on a complex biomarker selected trial impacted by both the pandemic and the war in Ukraine.
  • Pimivalimab is also being assessed in the SELECT Phase 2 clinical trial (NCT04549025) in combination with vopratelimab.
  • Although Jounce believes that the expectations reflected in the forward-looking statements are reasonable, Jounce cannot guarantee such outcomes.

Innovent Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies

Retrieved on: 
Wednesday, August 24, 2022
Safety, Chemistry, Food and Drug Administration, Integrity, Toxicity, R & D, Interleukin 2, CD4, PD-1, Company, MD Anderson Cancer Center, Social conditions in Honduras, Patient, Cancer, Food, Senior, CMC, Sintilimab, Lymphoma, HKEX, Trial of the century, NDA, R, NMPA, Adalimumab, Immunotherapy, Stock exchange, News, Eli Lilly and Company, Marketing, Nature, Control, Ophthalmology, Motherboard, IND, HK, Autoimmunity, Bevacizumab, CD8, Eli Lilly, Innovation Academy Charter School, Clinical trial, Environment, Pharmaceutical industry, Vaccine, Fine chemical, Ramucirumab, Regulatory T cell, Spotlight Innovation, Incyte

Dr. Hui Zhou, Senior Vice President of Innovent,stated:"Most patients will develop primary or secondary resistance after treatments of immune checkpoint inhibitors.

Key Points: 
  • Dr. Hui Zhou, Senior Vice President of Innovent,stated:"Most patients will develop primary or secondary resistance after treatments of immune checkpoint inhibitors.
  • We are looking forward to the positive results of IBI363 in patients with advanced solid tumors or lymphoma.
  • IBI363 is our first molecule to initiate clinical study in Australia, which marks a solid step of Innovent's global innovation strategy.
  • Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts.

Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME

Retrieved on: 
Tuesday, August 23, 2022
Literature, Neoplasm, Patient, Adoptive cell transfer, Cancer, PRAME, Synovial sarcoma, NASDAQ, Engineering, Evelyn, Nature, CD8, Head, Interim, Nivolumab, Body surface area, LinkedIn, Forward-looking statement, SEC, Cell, Uveal melanoma, CD4, University of Texas Health Science Center at Houston, Population, Twitter, CD19, Terminology, Clinical trial, Melanoma, Trial of the century, TCR, SITC, Vaccine, Medical imaging, Pharmaceutical industry, Instagram

The 2nd generation TCR-T IMA203CD8 aims to further enhance depth and durability of anti-tumor responses and clinical outcomes of TCR-T targeting PRAME in patients with solid cancers.

Key Points: 
  • The 2nd generation TCR-T IMA203CD8 aims to further enhance depth and durability of anti-tumor responses and clinical outcomes of TCR-T targeting PRAME in patients with solid cancers.
  • PRAME is highly prevalent across several indications thereby supporting the programs potential to reach a broad patient population.
  • Todays milestone brings us closer to our goal of achieving long-lasting responses for a broad range of cancer patients having solid tumors that express PRAME.
  • The 2nd generation TCR-T IMA203CD8 is part of Immatics strategy to realize the full clinical potential of IMA203 TCR-T targeting PRAME.

Cervical Cancer Drugs: Industry Trends and Opportunity Forecast, 2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 15, 2022
Oncology, AIDS, Health, Consumer, Women, Pharmaceutical, Biotechnology, Woman, Z-100, Risk, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Inflammation, Novartis, Cervical cancer, Bristol Myers Squibb, Diagnosis, Bowen University, Growth, Cancer, Geography, College of Arts and Sciences, Prevalence, Allergan, Eli Lilly and Company, GlaxoSmithKline, Degenerative disease, Pessary, National, COVID-19, Company, Gel, Acquisition, CD4, ICH, Awareness, Human, CAGR, Forecasting, Alnylam Pharmaceuticals, Tablet, HIV, Vagina, Celgene, International Council, Harmonization, Immune system, Disease, Birth control, Pharmaceutical industry, Oil, Retail, Pfizer, Cidofovir

The "Cervical Cancer Drugs Global Market Report 2022, Cancer Type, Drug Type, Distribution Channel" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Cancer Drugs Global Market Report 2022, Cancer Type, Drug Type, Distribution Channel" report has been added to ResearchAndMarkets.com's offering.
  • North America is the largest region in the cervical cancer drugs market in 2021.
  • The increasing prevalence of HIV (Human immunodeficiency virus) in women is driving the growth of the cervical cancer drugs market.
  • The lack of awareness and other misconceptions about cervical cancers hinder the growth of the cervical cancer drugs market.

HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200301 in Combination with Tislelizumab in Patients with DIS™ Selected Advanced Solid Tumors

Retrieved on: 
Monday, August 15, 2022
Research, Pharmaceutical, Oncology, Data Management, Technology, Artificial Intelligence, Health Technology, Clinical Trials, Science, Biotechnology, Stem Cells, Health, Antibody, Safety, CEO, CD8, Tislelizumab, Immunoglobulin G, Clinical trial, Open innovation, Cancer, NK, PD-1, TNFR2, Patient, Therapy, View, Innovation, CD4, Macrophage, Novartis, Intention, Immunology, DIS, Degenerative disease, Immune system, Pharmaceutical industry, Medical device, Vaccine

Combination immunotherapy approaches have become a promising solution for harder to treat cancers, said Luigi Manenti, M.D., Chief Medical Officer at HiFiBiO Therapeutics.

Key Points: 
  • Combination immunotherapy approaches have become a promising solution for harder to treat cancers, said Luigi Manenti, M.D., Chief Medical Officer at HiFiBiO Therapeutics.
  • We are excited to explore whether HFB200301 in combination with tislelizumab can further improve patient outcomes in DIS selected cancers.
  • HiFiBiO is proud to highlight the potential of our DIS platform to rapidly advance novel therapeutics like HFB200301 from targets to patients.
  • www.hifibio.com
    HiFiBiO Therapeutics, HiFiBiO Therapeutics logo, and DIS are trademarks of HiFiBiO and its affiliates.